Dallas, Texas (PRWEB) March 06, 2014
Purchase the report for 20% discount. Offer valid until 31st March 2014.
The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.
Europe is the second largest market for orphan drugs. In the European region, rare disease is considered to be a priority area and research in this field is given high importance by the EU Framework Programmes for Research and Technological Development (FP) ever since the early 1990s. Increasing the utilization of scarce resources and coordinating research efforts are the basic factors which have been responsible for success in the European rare diseases market. However, the absence of an exhaustive rare disease classification, standard terms of reference and a harmonized regulatory requirement, has always been a challenge in this region, which is currently impacting the global sharing of information, data and samples which would boost the research further.
Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=311703.
The concept of rare diseases and the idea that a special attention needs to be given to this sector has been taking shape in Europe since the 1990s. ever since then the political aspects and initiatives related to orphan medicinal products have been emerging at both the EU level and at the level of member states individually.
Many member states in the EU have led the way during the 1990s in the space of orphan medicinal products, the result of which took the shape of the first European legislative text concerning rare diseases called the Orphan Medicinal Product Regulation. This Regulation was adopted in 1999 and came into effect in 2000.
Complete report available at http://www.marketreportsonline.com/311703.html.
Major points from Table of Contents (http://www.marketreportsonline.com/311703.html) are listed below:
Table of Contents
1. Introduction to Orphan Drugs
2. Why Shift from Non Orphan to Orphan Drugs?
3. Europe Orphan Drug Market Outlook
4. Europe Regulatory Framework for Orphan Drugs
5. Europe Orphan Drug Pipeline Insight by Phase & Indication
6. Marketed Orphan Drugs in Europe: Brand Name & Indication
7. Key Issue to be Addressed
8. Competitive Landscape
Related Reports on Pharmaceuticals Market:
US Orphan Drug Market Outlook 2018 at http://www.marketreportsonline.com/311704.html.
Global Proton Therapy Market: Trends & Opportunities (2013-2018) at http://www.marketreportsonline.com/311709.html.
MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the pharmaceuticals market, MarketReportsOnline.com offers research studies on agriculture, consumer goods, chemicals, food and beverages, environment, biotechnology, agriculture, mining & utilities, healthcare, retail, medical devices and much more.